In a post hoc subgroup analysis of 139 participants with polypoidal choroidal vasculopathy from a phase 3 RCT, aflibercept 8 mg every 12 or 16 weeks showed week-48 BCVA gains similar to 2 mg every 8 weeks (+9.5, +8.4 vs +9.1 letters).
Secondary analysisn = 139
Lee et al. Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial